Wirksamkeit im Vergleich

Markiert sind besonders wichtige Quellen.

• Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26,

  cdc.gov, hinzugefügt am 25.10.2022, wichtige Quelle

• Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

  nejm.org, hinzugefügt am 26.04.2022, wichtige Quelle

• mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

  science.org, hinzugefügt am 03.04.2022, wichtige Quelle

• Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection

  cell.com, hinzugefügt am 21.12.2021, wichtige Quelle

• Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans

  nejm.org, hinzugefügt am 18.12.2021, wichtige Quelle

• Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

  thelancet.com, hinzugefügt am 06.12.2021, wichtige Quelle

• SARS-CoV-2: Schutzwirkung von BNT162b2 lässt etwas schneller nach als bei mRNA-1273

  aerzteblatt.de, hinzugefügt am 30.10.2021, wichtige Quelle

• Susceptibility to SARS-CoV-2 Omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination

  cell.com, hinzugefügt am 26.10.2022

• Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not?

  science.org, hinzugefügt am 06.06.2022

• Humoral and cellular immune memory to four COVID-19 vaccines

  cell.com, hinzugefügt am 30.05.2022

• Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study

  journals.plos.org, hinzugefügt am 27.05.2022

• Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised tr

  thelancet.com, hinzugefügt am 13.05.2022

• SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022

  eurosurveillance.org, hinzugefügt am 09.05.2022

• Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine

  nature.com, hinzugefügt am 09.05.2022

• Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 Infection and Severe Disease in Singapore

  academic.oup.com, hinzugefügt am 01.05.2022

• Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

  journalofinfection.com, hinzugefügt am 26.04.2022

• Vaccine effectiveness against infection and COVID-19-associated hospitalisation with the Omicron (B.1.1.529) variant after vaccination with the BNT162b2 or mRNA-1273 vaccine: A nationwide Danish cohort study

  researchsquare.com, hinzugefügt am 08.04.2022

• Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study

  thelancet.com, hinzugefügt am 03.04.2022

• Evaluating COVID-19 vaccines in the real world

  thelancet.com, hinzugefügt am 22.03.2022

• Humoral and cellular immune memory to four COVID-19 vaccines

  biorxiv.org, hinzugefügt am 22.03.2022

• Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study

  thelancet.com, hinzugefügt am 22.03.2022

• Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study

  thelancet.com, hinzugefügt am 16.03.2022

• Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

  nejm.org, hinzugefügt am 06.03.2022

• SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

  nejm.org, hinzugefügt am 17.02.2022

• mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants

  nature.com, hinzugefügt am 17.02.2022

• Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period

  jamanetwork.com, hinzugefügt am 24.01.2022

• Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

  nejm.org, hinzugefügt am 13.01.2022

• Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans

  nejm.org, hinzugefügt am 13.01.2022

• Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina

  nejm.org, hinzugefügt am 13.01.2022

• Covid-19 Vaccine Effectiveness in New York State

  nejm.org, hinzugefügt am 13.01.2022

• Neue Daten aus GroßbritannienBis zu 80 Prozent Schutz: Das ist die beste Booster-Kombination gegen Omikron

  focus.de, hinzugefügt am 31.12.2021

• Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

  medrxiv.org, hinzugefügt am 23.12.2021

• Aufwändige Studie Eine Booster-Kombination enttäuscht

  n-tv.de, hinzugefügt am 09.12.2021

• Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants

  wwwnc.cdc.gov, hinzugefügt am 09.12.2021

• Covid-19 Vaccine Effectiveness in New York State

  nejm.org, hinzugefügt am 07.12.2021

• SARS-CoV-2: Heterologe Impfung führt zu höheren Antikörpertitern

  aerzteblatt.de, hinzugefügt am 07.12.2021

• Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine

  medrxiv.org, hinzugefügt am 06.12.2021

• Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

  clinicalmicrobiologyandinfection.com, hinzugefügt am 06.12.2021

• Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans

  nejm.org, hinzugefügt am 04.12.2021

• Covid-19 Vaccine Effectiveness in New York State

  nejm.org, hinzugefügt am 02.12.2021

• Direct Comparison of Antibody Responses to Four SARS-CoV-2 Vaccines in Mongolia

  cell.com, hinzugefügt am 19.11.2021

• Monitoring reports of the effectiveness of COVID-19 vaccination

  gov.uk, hinzugefügt am 19.11.2021

• Pfizer-BioNTech vaccination with Moderna booster jab has ‘slight edge’ in reducing COVID-19 infection risk: Ong Ye Kung

  channelnewsasia.com, hinzugefügt am 19.11.2021

• Covid-19 Vaccine Effectiveness Assessment in Chile

  cdn.who.int, hinzugefügt am 15.11.2021

• Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar

  medrxiv.org, hinzugefügt am 14.11.2021

• Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

  jamanetwork.com, hinzugefügt am 05.11.2021

• SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

  science.org, hinzugefügt am 05.11.2021

• Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity

  cdc.gov, hinzugefügt am 04.11.2021

• BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

  nature.com, hinzugefügt am 04.11.2021

• Is Moderna Really Better Than Pfizer—Or Is It Just a Higher Dose?

  theatlantic.com, hinzugefügt am 01.11.2021

• SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA- versus vector-based vaccination in the general Dutch population

  medrxiv.org, hinzugefügt am 29.10.2021

• Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers

  mdpi.com, hinzugefügt am 25.10.2021

• https://www.nejm.org/doi/full/10.1056/NEJMc2113864

  nejm.org, hinzugefügt am 22.10.2021

• Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY

  medrxiv.org, hinzugefügt am 20.10.2021

• Long-term predictions of humoral immunity after two doses of BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex

  medrxiv.org, hinzugefügt am 20.10.2021

• Time-varying effectiveness of the mRNA-1273, BNT162b2 and Ad26.COV2.S vaccines against SARS-CoV-2 infections and COVID-19 hospitalizations and deaths: an analysis based on observational data from Puerto Rico

  medrxiv.org, hinzugefügt am 20.10.2021

Keine Quelle enthält diesen Text.